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Background: Diabetes self-care by patients has been shown to assist in the reduction of disease severity and
associated medical costs. We compared the effectiveness of two different diabetes self-care interventions on
glycemic control in a racially/ethnically diverse population. We also explored whether reductions in glycated
hemoglobin (HbA1c) will be more marked in minority persons.
Methods: We conducted an open-label randomized controlled trial of 376 patients with type 2 diabetes
aged ≥18 years and whose last measured HbA1c was ≥7.5% (≥58 mmol/mol). Participants were randomized to:
1) a Chronic Disease Self-Management Program (CDSMP; n = 101); 2) a diabetes self-care software on a personal
digital assistant (PDA; n = 81); 3) a combination of interventions (CDSMP + PDA; n = 99); or 4) usual care (control;
n = 95). Enrollment occurred January 2009-June 2011 at seven regional clinics of a university-affiliated multi-specialty
group practice. The primary outcome was change in HbA1c from randomization to 12 months. Data were analyzed
using a multilevel statistical model.
Results: Average baseline HbA1c in the CDSMP, PDA, CDSMP + PDA, and control arms were 9.4%, 9.3%, 9.2%, and
9.2%, respectively. HbA1c reductions at 12 months for the groups averaged 1.1%, 0.7%, 1.1%, and 0.7%,
respectively and did not differ significantly from baseline based on the model (P = .771). Besides the participants in
the PDA group reporting eating more high-fat foods compared to their counterparts (P < .004), no other significant
differences were observed in participants’ diabetes self-care activities. Exploratory sub-analysis did not reveal any
marked reductions in HbA1c for minority persons but rather modest reductions for all racial/ethnic groups.
Conclusions: Although behavioral and technological interventions can result in some modest improvements in
glycemic control, these interventions did not fare significantly better than usual care in achieving glycemic
control. More research is needed to understand how these interventions can be most effective in clinical practice.
The reduction in HbA1c levels found in our control group that received usual care also suggests that good routine
care in an integrated healthcare system can lead to better glycemic control.
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Diabetes education, particularly evidence-based approaches
to diabetes self-care, is considered critical to achieving suc-
cessful outcomes in diabetes management [1-3]. Several
national organizations including the American Diabetes
Association and the American Association of Diabetes
Educators consider self-care an essential component of ef-
fective diabetes management [4-6]. Different approaches to
improving glycemic control, the hallmark of diabetes treat-
ment, have involved enhancing diabetes self-care processes
using behavioral and technological programs. However,
current literature provides mixed results on the effective-
ness of self-care interventions in glycemic control and
other related health measures. While most studies report
positive short-term effects [7-9], others found no statisti-
cally significant differences in the longer term [10-12].
Behavioral interventions, such as the Chronic Disease
Self-Management Program (CDSMP), offer the potential
to improve overall health of individuals with diabetes,
while preventing further decline in health status [13-15].
In a study evaluating changes in health behaviors, health
status, and hospitalizations, CDSMP was found effective
in improving health generally and resulted in lower
hospitalization rates [13]. A recent meta-analysis of vari-
ous self-care programs concluded a positive, but modest
effect on numerous health-related outcomes [15]. How-
ever, until recently the CDSMP has not been delivered
to substantial numbers of participants from racially/
ethnically diverse backgrounds outside the original studies
conducted by program developers [16].
Recent research also endorses the positive impact of
technological interventions on diabetes management. As
the use of portable blood glucose meters in the late
1980s began to change the way diabetes patients were
monitored [17,18], researchers began experimenting
with new technologies such as electronic diaries and the
personal digital assistant (PDA) to assist with diabetes
self-care in the early 2000s [19-21]. Diabetes self-care
delivered via information technology is becoming an im-
portant factor in daily management for clinicians and
patients [22]. These methods have been reported to as-
sist patients to easily and accurately keep track of their
self-care performance through immediate feedback [23].
In a pilot study, we tested the PDA’s feasibility in enhan-
cing self-care activities of patients with type 2 diabetes
mellitus (T2DM), identified which patients would benefit
most from this technology, and assessed the effective-
ness of our intervention on glycemic control [24]. The
mean HbA1c decreased from 9.7% (83 mmol/mol) at
baseline to 8.0% (64 mmol/mol) in 18 of 43 patients
who completed the 6-month follow-up. The change in
HbA1c was larger among regular and frequent PDA
users [25]. This study did not, however, explore racial/
ethnic differences or health disparities.Despite concerted federal and state attempts to reduce
health disparities over the past decades, national statis-
tics still document substantial disparities in reported
rates of diabetes for racial/ethnic minorities compared to
non-minorities. For example, numerous studies docu-
ment that African Americans and Hispanics experience
higher rates of T2DM and associated cardiovascular dis-
eases than other segments of the United States (U.S.)
[26-29]. After adjusting for population age differences,
2007–2009 national survey data for people ≥20 years in-
dicated that 7.1% of non-Hispanic whites, 8.4% of Asian
Americans, 11.8% of Hispanics/Latinos, and 12.6% of
African Americans had diagnosed diabetes [30]. Rates
are also higher in rural and medically underserved pop-
ulations due to the relative scarcity of healthcare pro-
viders, reduced access to needed healthcare, and less
available electronic information systems [31-33]. As
such, reducing and ultimately eliminating health dispar-
ities to achieve health equity for all groups continues to
be a major public health objective [34]. While racial/
ethnic minorities may still have reduced access to health-
care [35], their ownership rates of new technologies, such
as mobile devices, may be at par with or even higher than
their non-minority counterparts [36,37] and therefore
benefit more from a technologically-assisted intervention
such as use of a PDA.
The aim of this study was to test the effectiveness of
two different diabetes self-care interventions on glycemic
control in a large integrated healthcare organization in
Central Texas that serves large racially/ethnically diverse
populations. We also explored whether reductions in
HbA1c will be more marked in minority persons with
T2DM. This study is innovative in its comparison of be-
havioral and technological interventions as well as a
combination of both interventions. Additionally, both
clinical and behavioral outcomes were measured.
Methods
Design
This study was an open-label randomized controlled trial
(RCT) designed to evaluate the effectiveness of two differ-
ent T2DM self-care interventions (implemented singly and
in combination) on glycemic control. Designed with the ac-
knowledgment that both patients and researchers would be
aware of the random assignment, the protocol consisted of
screening potential subjects for eligibility, randomization to
one of four study arms, and following them over a 24-
month period. The primary end-point was change in gly-
cated hemoglobin (HbA1c) from randomization/baseline to
12 months of follow-up. The study protocol was ap-
proved by the Institutional Review Boards (IRB) of Scott
& White Healthcare System and Texas A&M Health
Science Center. All qualified participants accepted the
conditions of the study and gave informed written
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January 2009-June 2011 and data collection was com-
pleted in July 2012. We adhered to the CONSORT
protocol [38].
Setting, participants, and recruitment
Participants were recruited from seven participating clinics
of a large integrated healthcare system, a university-
affiliated, multi-specialty group practice associated with a
250,000-member Health Maintenance Organization in
Central Texas. These clinics were selected based on their
relatively higher numbers and overall percentage of
African American and Hispanic patients diagnosed with
T2DM. Potential participants were identified through
electronic medical records if they: 1) had a diagnosis of
T2DM; 2) were ≥18 years; 3) had a lab assessed HbA1c
value ≥7.5% (≥58 mmol/mol) within the last six months;
and 4) were able to communicate in English. Subjects
were excluded if they: 1) had documented reports of alco-
holism or drug abuse; 2) were pregnant or planning to
become pregnant within 12 months; or 3) were unwilling
to sign an informed consent. Recruitment was solicited
by physicians within the seven clinics who agreed to in-
vite their patients to participate in the study.
Physicians were provided with IRB approved
invitation-to-participate letters and a list of their T2DM
patients meeting the threshold HbA1c level at their last
visit. Contact was initiated with potential subjects
through physician-sent letters, describing the study and
requesting a completed screening enrollment card if in-
terested. Subjects who returned a screening enrollment
card were contacted by project coordinators, who pro-
vided additional information and screened them to de-
termine eligibility. To verify the inclusion and exclusion
criteria, subject permission was obtained to review their
medical records. Other recruitment strategies included
oral referrals by physicians and patient educators and
posting messages in waiting areas of study clinics.
Lab assessments were continuously monitored at each
phase of recruitment to ensure enrolled participants had
HbA1c values ≥7.5% (≥58 mmol/mol) within the last six
months since individuals who previously met this criterion
may no longer fulfill that requirement at orientation. A
follow-up telephone interview was conducted to deter-
mine participation interest. Lab results were screened to
ensure participant met qualifying HbA1c and if needed,
tests were scheduled.
Interventions
Consenting subjects were randomized to one of four
arms: 1) CDSMP; 2) PDA; 3) a combination of both in-
terventions (CDSMP + PDA); or 4) usual care (control).
A fixed, equal allocation stratified randomization pro-
cedure was utilized, stratifying by clinic setting and race/ethnicity using Stata (version 9.2, 2006, StataCorp, LP,
College Station, TX).
Participants randomized to the CDSMP arm were in-
vited to attend a 6-week, classroom-based program for
diabetes self-management. The effectiveness of CDSMP
has been described elsewhere [13]. With the goal of in-
creasing self-efficacy to ultimately decrease chronic
disease related symptoms and avoidable healthcare
utilization, CDSMP teaches participants techniques to
facilitate enhanced decision making, action planning,
and effective communication. CDSMP workshops were
hosted in clinical environments and community-based
settings. While fidelity to the individual classes was not
monitored, CDSMP license requires that lay leaders use
pre-scripted materials and that experienced master
trainers/lay leaders (who underwent the four-day train-
ing program) lead the workshops.
Those randomized to the PDA arm were taught to use
a diabetes self-care software, Diabetes Pilot™ (Digital
Altitudes, Arlington Heights, IL), that was developed for
the PalmOS® (Palm, Sunnyvale, CA) which was loaded
on to the Tungsten™ E2 handheld device. The Diabetes
Pilot allowed recording and some monitoring of blood
glucose, blood pressure, medication usage, physical ac-
tivity, and dietary intake on the PDA. One-on-one in-
struction by a project coordinator covering key areas
such as data entry, food database utilization, and re-
ports/graphing features was provided. Participants were
instructed to enter information throughout the day and
were encouraged to input daily. An instructional manual
was provided and participants were asked to contact
project coordinators with additional concerns/questions.
Although proficiency with PDA use was not evaluated
and individuals were provided additional guidance upon
request, training effectiveness was not assessed.
Participants randomized to the CDSMP + PDA arm
were given both interventions while those randomized
to the control arm did not receive any treatment other
than their usual clinical diabetes care, along with some
publicly available Texas Diabetes Council patient educa-
tion materials.
Data collection
Study measures were obtained at orientation and at
every six months over the 24 months of follow-up. Par-
ticipants received monetary compensation in the form of
a gift card for travel expenses and time, consisting of
$20 at orientation and at the 12- and 24-month follow-
up visits.
At orientation, a questionnaire was administered to
obtain information on: 1) demographics including age,
gender, and race/ethnicity; 2) technological experiences
(e.g., any experience using computers, the internet, and
a PDA); 3) self-reported health-related quality of life
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not good); 4) diabetes self-care activities (number of days,
0–7, that any specific self-care activity was performed in
the past week); 5) pain and fatigue measures (on a scale of
1–10, 1 indicating none and 10 severe); and 6) physical ac-
tivity measures (e.g., number of physically active days in
the past week). Questionnaires were administered every
6 months up to the 24-month follow-up visit. However, as
our primary end point was 12-months, analyses were only
conducted for this time period.
Anthropometric data, height, weight, and body mass
index (BMI) and blood pressures were obtained at orien-
tation and at subsequent follow-up visits. Participants
who were unable to come in for their follow-up appoint-
ments had their height, weight, and blood pressure data
abstracted from electronic health records (EHRs). Mea-
sures recorded fell within the range of 10 days prior to
and 45 days after participants’ scheduled follow-up dates.
This was done to obtain participant visits as close to
their target dates as possible, but also allow for enough
time after the target date to accommodate for scheduling
errors (i.e., missed appointments, rescheduling).
Measures of HbA1c were collected from EHRs dating
back six months prior to orientation to the last day of
study participation. If a participant did not have any
HbA1c value within the EHR for any particular follow-
up visit, a lab test was scheduled to obtain a measure. Of
the HbA1c collected six months prior to orientation, the
value measured closest to the orientation date was con-
sidered as the baseline HbA1c value.
Definition of a completed follow-up participation
A participant was considered to have completed a follow-
up if there was an available HbA1c within the designated
follow-up period, i.e., within the cut-off dates, defined as
45 days after the scheduled follow-up dates. For the 6-
month follow-up measure, if at least one HbA1c was avail-
able after baseline and before the 6-month cut-off, the
participant was considered to have completed a follow-up.
For the 12-month follow-up measure, the designated range
was between the 6-month cut-off date and the 12-month
cut-off date. Participants who were unable to complete an
assessment at one time period were not excluded from fu-
ture assessments. For instance, if a participant did not have
any HbA1c measured within the specified time period for
their 6-month follow-up but had one available for their 12-
month follow-up they were considered to have completed
the 12-month follow-up, but not the 6-month.
Outcome measures
The primary study outcome measure was change in
HbA1c from randomization to 12 months of follow-up.
Secondary outcome measures included BMI and blood
pressure, along with several self-management behavioralmeasures (e.g., foot care) from randomization to 12 months
of follow-up.
Statistical analysis
Analysis was based on intent-to-treat. Descriptive statis-
tics were used to describe baseline demographic, an-
thropometric, and clinical characteristics by study arm.
Analysis of variance (ANOVA) was used to compare
average changes in self-management behavior between
study arms. To determine whether treatments had an ef-
fect on the rate of change in the level of HbA1c over
time, we used a multilevel statistical model that included
time as a continuous variable, measured in days, where
0 = baseline. The lowest level of the hierarchy (level 1) in
this multilevel modeling was repeated measurements of
HbA1c on each subject, with the participants themselves
constituting the second level of the hierarchy (level 2).
Forward selection was utilized, in which powers of time
were added one at a time to the base model including
treatment group effects only. Time and treatment effects
were then added gradually and evaluated with likelihood
ratio tests to assess any effect modification. HbA1c
values included in the analysis were those falling within
the time frame of six months prior to orientation until
the 12-month follow-up cut-off point.
To explore whether health improvements following the
interventions were more marked in racial/ethnic minority
patients vs. non-Hispanic white populations, we ran an-
other model that contained treatment by race/ethnicity
interaction terms to test for differential impact of treatment
by race/ethnicity. All analyses were conducted using Stata
(version 12, 2012, StataCorp, LP, College Station, TX).
Sample size estimation was based on the two-level
model for longitudinal change in HbA1c using the ap-
proximation formula by Fitzmaurice, et al [39]. The sam-
ple size estimation, based on 80% power and a two-sided
significance level of .05, indicated that 75 participants per
treatment group would be required to detect a statistically
significant change in HbA1c of 0.5% for any pair-wise
comparison of the treatment groups and the control
group. Anticipating an attrition rate of 25%, we sought to
enroll 100 patients in each arm so as to end up with
the designated sample size. We also sought to achieve
50% minority (African American and Hispanics) and 50%
non-minority participation within the study by over enrol-
ling minority patients by an additional 30-40% so as to be
able to conduct sub-analysis by race/ethnicity.
Results
Subject enrollment, participation, retention, and
adherence
A total of 5,098 subjects were contacted by mail with
the introductory, invitation-to-participate letter describ-
ing the purpose and details of the study. Of these, 3,201
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yielding HbA1c values <7.5% (<58 mmol/mol) or our in-
ability to contact them. Of the remaining 1,897 potential
subjects, 922 expressed an interest. However, 546 were
ineligible based on HbA1c values <7.5% (<58 mmol/
mol), lack of study interest, or inability to communicate
in English, yielding 376 subjects who were subsequently
randomized.
After 6 months of follow-up, 18 participants withdrew
either on their own or due to death. Of this number, 7,
10, and 1 were from the PDA, CDSMP + PDA, and con-
trol group, respectively. The 6-month follow-up comple-
tion rates were 89%, 79%, 79%, and 91% for the CDSMP,
PDA, CDSMP + PDA, and control group, respectively.
After 12 months of follow-up, an additional 33 with-
drew; 15 from the PDA group, 17 from the CDSMP +
PDA group, and 1 from the controls, yielding 12-month
follow-up completion rates of 85%, 64%, 64%, and 78%
for the CDSMP, PDA, CDSMP + PDA, and control
groups, respectively. The flow diagram of participant en-
rollment and disposition is summarized in a consort
table in Figure 1.
Of the participants assigned to the CDSMP and
CDSMP + PDA arms who started, 75.6% and 72.7%, re-
spectively, attended 4 of 6 sessions required for successful
completion. Participants assigned to the CDSMP + PDA
and PDA arms made an average of 359 and 342 entries,
respectively, on their PDAs over the one-year study
period.Figure 1 Consort table.Demographic data and baseline comparison of study
population
Demographic and baseline clinical characteristics were
generally comparable among the study groups (Table 1).
The mean age of participants was 57.6 ± 10.9 years.
Slightly more than a third (36.4%) was of minority status,
self-reporting as either African American or Hispanic. The
majority of participants received post-secondary educa-
tion; 40% had attended some college or vocational school,
20% were college graduates, and 13% had completed
higher forms of education. Approximately one-third re-
ported annual incomes greater than $50,000, while almost
40% reported annual incomes between $25,000 and
$49,999.
An overwhelming majority (92.9%) of the participants
were either overweight or obese, with a mean BMI of
34.3 ± 7.4 kg/m [2]. While measures of systolic blood
pressure were comparable among study arms, with a
mean of 134.8 ± 19.3 mmHg, measures of diastolic blood
pressure were significantly different (P < 0.002). The
mean baseline HbA1c for participants was 9.3 ± 1.6%
and did not differ significantly among the four groups.
Changes in HbA1c from baseline to 12 Months
There were modest reductions in BMI and blood pres-
sure from baseline to 12 months of follow-up for all four
groups (table not shown). Similar results were observed
with changes in HbA1c from baseline to 12 months of
follow-up. Figure 2 displays lowess curves or trends of
Table 1 Selected characteristics of study population at baseline
Characteristics of participants CDSMP PDA CDSMP + PDA Controls All
n = 101 n = 81 n = 99 n = 95 n = 376
Age (years), No. (%)
18-34 4 (4.0) 1 (1.2) 2 (2.0) 1 (1.1) 8 (2.1)
35-64 77 (76.2) 55 (67.9) 71 (71.7) 69 (72.6) 272 (72.3)
65 or older 20 (19.8) 25 (30.9) 26 (26.3) 25 (26.3) 96 (25.5)
Gender, No. (%)
Female 54 (53.5) 47 (58.0) 53 (53.5) 53 (55.8) 207 (55.1)
Male 47 (46.5) 34 (42.0) 46 (46.5) 42 (44.2) 169 (44.9)
Minoritya
No 60 (59.4) 51 (63.0) 65 (65.7) 63 (66.3) 239 (63.6)
Yes 41 (40.6) 30 (37.0) 34 (34.3) 32 (33.7) 137 (36.4)
Hispanic, No. (%)
No 81 (80.2) 62 (77.5) 76 (76.8) 80 (84.2) 299 (79.7)
Yes 20 (19.8) 18 (22.5) 23 (23.2) 15 (15.8) 76 (20.3)
Race-ethnicity, No. (%)
Non-Hispanic white 58 (57.4) 49 (60.5) 61 (61.6) 58 (61.1) 226 (60.1)
Non-Hispanic black 21 (20.8) 11 (13.6) 12 (12.1) 17 (17.9) 61 (16.2)
Hispanic 20 (19.8) 19 (23.5) 22 (22.2) 15 (15.8) 76 (20.2)
Other 2 (2.0) 2 (2.5) 4 (4.0) 5 (5.3) 13 (3.5)
Education, No. (%)
Less than high school 6 (5.9) 4 (4.9) 3 (3.0) 3 (3.2) 16 (4.3)
Some high school 4 (4.0) 3 (3.7) 8 (8.1) 1 (1.1) 16 (4.3)
High school graduate 16 (15.8) 20 (24.7) 17 (17.2) 21 (22.1) 74 (19.7)
Some college/vocational school 46 (45.5) 34 (42.0) 33 (33.3) 36 (37.9) 149 (39.6)
College graduate 16 (15.8) 13 (16.1) 24 (24.2) 21 (22.1) 74 (19.7)
Graduate school 13 (12.9) 7 (8.6) 14 (14.1) 13 (13.7) 47 (12.5)
Income, No. (%)
< $15,000 12 (11.9) 11 (13.6) 7 (7.1) 9 (9.6) 39 (10.4)
$15,000 - $24,999 11 (10.9) 14 (17.3) 19 (19.2) 16 (17.0) 60 (16.0)
$25,000 - $49,999 41 (40.6) 37 (45.7) 32 (32.3) 30 (31.9) 140 (37.3)
$50,000 - $75,000 12 (11.9) 12 (14.8) 23 (23.2) 17 (18.1) 64 (17.1)
> $75,000 12 (11.9) 6 (7.4) 14 (14.1) 14 (14.9) 46 (12.3)
Prefer not to answer 13 (12.9) 1 (1.2) 4 (4.0) 8 (8.5) 26 (6.9)
BMI (kg/m2), No. (%)
Normal 10 (10.3) 5 (6.3) 3 (3.2) 8 (8.7) 26 (7.1)
Overweight 25 (25.8) 15 (18.8) 18 (19.0) 17 (18.5) 75 (20.6)
Obese 62 (63.9) 60 (75.0) 74 (77.9) 67 (72.8) 263 (72.3)
Age (years), Mean (±SD) 56.4 (±10.8) 57.7 (±10.8) 57.7 (±10.3) 58.5 (±11.9) 57.6 (±10.9)
BMI (kg/m2), Mean (±SD) 33.5 (±8.0) 35.3 (±7.3) 34.6 (±6.3) 33.9 (±7.7) 34.3 (±7.4)
SBP (mm/Hg), Mean (±SD) 131.9 (±14.1) 138.5 (±21.2) 136.2 (±19.1) 132.9 (±21.7) 134.8 (±19.3)
DBP (mm/Hg), Mean (±SD)* 79.4 (±9.8) 73.6 (±11.0) 78.8 (±11.4) 75.8 (±13.6) 77.0 (±11.7)
HbA1c (%), Mean (±SD) 9.4 (±1.7) 9.3 (±1.6) 9.2 (±1.4) 9.2 (±1.6) 9.3 (±1.6)
aAfrican American or Hispanic.
*Significant p < 0.05.
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Figure 2 Lowess curves.
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results of the multilevel statistical model are presented
in Table 2. The reductions in HbA1c per day over the
12 months of follow-up for the control, CDSMP, PDA,
and CDSMP + PDA groups were 0.002%, 0.003%,
0.002%, and 0.003%, respectively, which translated to
HbA1c reductions of 0.7%, 1.1%, 0.7%, and 1.1%, re-
spectively, from baseline to 12 months of follow-up.
However, the main effect of treatment was not statisti-
cally significant (P = 0.771), implying no significant
changes in HbA1c by treatment assignment. In addition,
interactions with treatment-by-time and treatment-
by-time squared did not reach statistical significance at
P < 0.05.
Diabetes self-care activity monitoring during the
intervention
The mean difference in the number of days (within the
last 7 days), from baseline to 12 months of follow-up
that participants reported using specific diabetes self-care activity features, measured by the Summary of
Diabetes Self-Care Activities instrument, to assist with
diabetes self-care activity monitoring were compared be-
tween treatment arms (table not shown). Participants in
the PDA group reported eating more high-fat foods
compared to their counterparts (P < .004). No other
significant differences were observed.
Exploratory sub-analysis by race/ethnicity
Health improvements following the introduction of self-
management protocols were examined by race/ethnicity
to explore whether there were any significant differ-
ences. Lowess curves for the raw data for HbA1c values
by race/ethnicity are displayed in Figure 2. For this ana-
lysis, participants who self-reported as African American
(n = 44), Hispanic (n = 61), or Caucasian (n = 168) were
included in the model. Modest reductions occurred in
HbA1c from baseline to 12 months of follow-up for all
racial/ethnic groups (Table 3). However, the likelihood
ratio test indicated that the respective treatments had a
Table 2 Model of HbA1c values of participants by treatment
Model parameter b(SE) 95% CI Z P-value
Fixed effects
b0 (intercept) 9.029 (0.144) 8.746, 9.312 62.52 <0.001
b1 (Time) −0.002 (0.001) −0.004, -0.001 −3.13 0.002
b2 (Time
2) 1.70 × 10−6 (2.27 × 10−6) −2.75 × 10−6, 6.16 × 10−6 0.75 0.453
b3 (CDSMP) 0.114 (0.201) −0.280, 0.508 0.57 0.571
b4 (PDA) 0.054 (0.214) −0.366, 0.473 0.25 0.802
b5 (CDSMP + PDA) −0.121 (0.204) −0.520, 0.278 −0.60 0.551
b6 (CDSMP × Time) −0.001 (0.001) −0.003, 0.001 −1.17 0.242
b7 (PDA × Time) 7.22 × 10
-5 (0.001) −0.002, 0.002 0.06 0.950
b8 ((CDSMP + PDA) × Time) −0.001 (0.001) −0.003, 0.002 −0.61 0.543
b9 (CDSMP × Time
2) 4.63 × 10−6 (3.16 × 10−6) −1.55 × 10−6, 1.08 × 10−5 1.47 0.142
b10 (PDA × Time
2) 2.04 × 10−6 (3.64 × 10−6) −5.09 × 10−6, 9.17 × 10−6 0.56 0.575
b11 ((CDSMP + PDA) × Time
2) 5.21 × 10−6 (3.47 × 10−6) −1.59 × 10−6, 1.20 × 10−5 1.50 0.133
Random effects
var(u1it × timeit) 0.002 (2.59 × 10
−4) 0.002, 0.003 9.30 <0.001
var(u0i) 1.257 (0.056) 1.153, 1.372 22.53 <0.001
var(eit) 0.870 (0.024) 0.825, 0.918 36.39 <0.001
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at P < 0.05. On average, Hispanics who received the
CDSMP + PDA intervention had a lower HbA1c com-
pared to Caucasians who received the usual care. How-
ever, there was no statistically significant difference in
HbA1c change over time by race/ethnicity. Additionally,
Hispanics reported washing their feet significantly more
than other racial/ethnic groups (P = 0.02) (table not
shown).
Discussion
In this study, we sought to evaluate the individual and
combined effects of two interventions – a behavioral
and a technological intervention – targeting glycemic
control via diabetes self-care. We found that participants
receiving any of the treatments had similar rates of
change in HbA1c over time compared to those who re-
ceived usual care. This finding was somewhat surprising
based on the results of our pilot study on PDA use to
enhance diabetes self-care [25] and the fact that CDSMP
has been found beneficial in lowering HbA1c among
people with high levels [13,14,40]. In our pilot study, we
found a 1.7% point reduction in HbA1c compared to the
relatively small reductions found in this study (0.7%-
1.1%). However, we also found a higher reduction in
HbA1c at 6 months of follow-up for two of our treat-
ment arms compared to 12 months of follow-up, sup-
porting prior literature on the diminution of
intervention effects over time [41]. In a meta-analysis of
the effects of self-monitoring of blood glucose relative to
usual care, an overall statistically significant decrease inHbA1c at 6 months of follow-up was reported. This ef-
fect, however, became non-significant at 12 months of
follow-up [9].
Our results also corroborate the findings of another
RCT group-based training for diabetes self-management,
which reported no significant differences in HbA1c
levels after 12 months of follow-up [10]. Nevertheless,
our findings are less encouraging than others. A RCT re-
ported a HbA1c reduction of 3.3% (13 mmol/mol) in the
intervention arm at 6 months, and concluded that self-
monitoring disease management strategy is able to im-
prove metabolic control, primarily through lifestyle
modifications leading to weight loss [8]. Another trial re-
ported a significant decrease in HbA1c of 0.3% in the
intervention group compared with the control group
[42]. However, more than 30% were lost to follow-up. In
our current study, it is important to note the improve-
ment in the control group over time, suggesting a high
level of routine diabetes care in an integrated healthcare
system, which may involve close monitoring and self-
care skill teaching as controls dropped 0.7% from base-
line to 12 months.
Besides participants in the PDA group reporting a
slightly higher intake of high-fat foods as was found in
our pilot study [25], we found no other significant differ-
ences in our participants’ diabetes self-monitoring activ-
ity behaviors. There is a debate in the self-management
field whether generic versus disease specific self-
management is more beneficial [16,43]. While our view
was that a generic program would be valuable for pa-
tients experiencing several comorbidities, more positive
Table 3 Model of HbA1c values of participants by race/ethnicity
Model parameter b(SE) 95% CI Z P-value
Fixed effects
b0 (intercept) 8.765 (0.179) 8.414, 9.117 48.87 <0.001
b1 (Time) −0.001 (0.001) −0.003, 0.001 −1.04 0.297
b2 (Time
2) −1.21 × 10−6 (2.92 × 10−6) −6.94 × 10−6, 4.52 × 10−6 −0.41 0.679
b3 (African American) 0.702 (0.374) −0.031, 1.435 1.88 0.061
b4 (Hispanic) 1.242 (0.396) 0.466, 2.018 3.14 0.002
b5 (CDSMP) 0.099 (0.254) −0.398, 0.597 0.39 0.696
b6 (PDA) 0.132 (0.266) −0.391, 0.654 0.49 0.621
b7 (CDSMP + PDA) 0.177 (0.252) −0.318, 0.671 0.70 0.483
b8 (CDSMP × African American) 0.247 (0.513) −0.759, 1.253 0.48 0.631
b9 (CDSMP × Hispanic) −0.699 (0.530) −1.738, 0.340 −1.32 0.187
b10 (PDA × African American) −0.620 (0.612) −1.820, 0.579 −1.01 0.311
b11 (PDA × Hispanic) −0.496 (0.542) −1.559, 0.566 −0.92 0.360
b12 ((CDSMP + PDA) × African American) −0.872 (0.575) −1.999, 0.254 −1.52 0.129
b13 ((CDSMP + PDA) × Hispanic) −1.226 (0.526) −2.256, -0.195 −2.33 0.020
b14 (CDSMP × Time) −0.002 (0.001) −0.004, 0.001 −1.20 0.229
b15 (PDA × Time) −1.62 × 10
−4 (0.002) −0.003, 0.003 −0.10 0.922
b16 ((CDSMP + PDA) × Time) −0.002 (0.001) −0.005, 0.001 −1.46 0.144
b17 (CDSMP × Time
2) 5.64 × 10−6 (4.22 × 10−6) −2.63 × 10−6, 1.39 × 10−5 1.34 0.181
b18 (PDA × Time
2) 1.81 × 10−6 (4.86 × 10−6) −7.71 × 10−6, 1.13 × 10−5 0.37 0.709
b19 ((CDSMP + PDA) × Time
2) 8.85 × 10−6 (4.35 × 10−6) 3.19 × 10−7, 1.74 × 10−5 2.03 0.042
b20 (Control × African American × Time) −0.001 (0.002) −0.005, 0.002 −0.80 0.426
b21 (Control × Hispanic × Time) −0.007 (0.002) −0.011, -0.002 −2.86 0.004
b22 (CDSMP × African American × Time) −0.001 (0.002) −0.004, 0.003 −0.33 0.743
b23 (CDSMP × Hispanic × Time) −0.003 (0.002) −0.007, 0.001 −1.44 0.149
b24 (PDA × African American × Time) 0.001 (0.003) −0.005, 0.007 0.21 0.837
b25 (PDA × Hispanic × Time) −0.003 (0.002) −0.007, 0.001 −1.61 0.108
b26 ((CDSMP + PDA) × African American × Time) 4.24 × 10
−4 (0.003) −0.006, 0.007 0.14 0.892
b27 ((CDSMP + PDA) × Hispanic × Time) 1.81 × 10
−4 (0.002) −0.004, 0.004 0.09 0.927
b28 (Control × African American × Time
2) 2.68 × 10−6 (5.64 × 10−6) −8.38 × 10−6, 1.37 × 10−5 0.47 0.635
b29 (Control × Hispanic × Time
2) 1.57 × 10−5 (7.17 × 10−6) 1.68 × 10−6, 2.98 × 10−5 2.19 0.028
b30 (CDSMP × African American × Time
2) 2.53 × 10−6 (5.48 × 10−6) −8.21 × 10−6, 1.33 × 10−5 0.46 0.645
b31 (CDSMP × Hispanic × Time
2) 5.54 × 10−6 (5.99 × 10−6) −6.20 × 10−6, 1.73 × 10−5 0.93 0.355
b32 (PDA × African American × Time
2) 2.53 × 10−6 (1.20 × 10−5) −2.09 × 10−5, 2.60 × 10−5 0.21 0.832
b33 (PDA × Hispanic × Time
2) 8.22 × 10−6 (6.56 × 10−6) −4.64 × 10−6, 2.11 × 10−5 1.25 0.210
b34 ((CDSMP + PDA) × African American × Time
2) −3.82 × 10−6 (1.08 × 10−5) −2.49 × 10−5, 1.73 × 10−5 0.36 0.722
b35 ((CDSMP + PDA) × Hispanic × Time
2) −2.75 × 10−6 (6.55 × 10−6) −1.56 × 10−5, 1.01 × 10−5 −0.42 0.674
Random effects
var(u1it × timeit) 0.002 (2.68 × 10
−4) 0.002, 0.003 9.00 <0.001
var(u0i) 1.206 (0.056) 1.102, 1.320 21.68 <0.001
var(eit) 0.879 (0.025) 0.832, 0.929 35.66 <0.001
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chronic disease self-management program was utilized
(which was not evidence-based at the time of initial pro-
gram selection for English speaking patients) [44].
Higher attrition among participants in the PDA and
CDSMP + PDA groups deserves some comment. No
doubt participant overburden with the extensive amount
of data entry requirement may have resulted in this attri-
tion. A similar attrition was observed in our pilot study
[25] and several others [20,45]. Although we instituted
several measures to mitigate this problem, such as pro-
viding intensive training via one-on-one instruction, sev-
eral participants expressed frustration with the device,
the program or both as their primary reason for discon-
tinuing PDA use. The arrival of the revolutionary iPhone
that coincided with our study may have also contributed
to the higher attrition in study arms with the PDA [46].
Indeed, PDA usage, while being obsolete today, was the
first foray in T2DM self-care via information technology.
However, it may be more beneficial to shift our focus from
diabetes self-management software designed for PDAs to
more mainstream devices such as smartphones and tab-
lets. These devices have already been accepted by the gen-
eral public and integrating diabetes self-management
programs on these platforms would yield a more seamless
transition into an individual’s daily routine.
Results from our exploratory racial/ethnic sub-analyses
were consistent with other studies in the literature. Con-
trary to our initial hypothesis, racial/ethnic differences in
glycemic control did not diminish significantly over time,
except for a slight reduction among Hispanics who re-
ceived the CDSMP+ PDA intervention. While we found
no statistically significant racial/ethnic differences in
HbA1c levels over time, Adams and colleagues noted per-
sistent “white-black differences” in HbA1c levels among
insured patients [47].
Our study had a few limitations that must be taken
into consideration in the interpretation of the findings.
There was differential dropout across interventions, sug-
gesting that some intervention strategies are more diffi-
cult to learn and maintain than others. However, this
initial analysis focused on an intent-to-treat analysis and
means. Other future analyses will examine impacts
among those who got recommended intervention dos-
ages and examine different quartiles. It is possible that
there could be a small but significant minority of partici-
pants who prove difficult to control and who thus mask
improvements among others. We also recommend more
careful monitoring of treatment fidelity to ascertain if
behavioral and technological interventions were consist-
ently delivered and enacted upon as recommended [48].
Due to the open label of our interventions, the behavior
of participants in different arms of the study managed in
the same clinics could have been affected by contact withthe protocols in the different arms. Additionally, even
though we tried to oversample minorities in order to ob-
tain 50% minority and 50% non-minority participation,
our final sample included only 34% minority participants.
This prevented further analyses of race/ethnicity differ-
ences, allowing us to only provide information on racial/
ethnic differences in an exploratory manner as the study
was not powered to detect racial/ethnic differences.
Finally, findings may not be completely generalizable to
adults with uncontrolled T2DM since only 49% of eligible
individuals screened by phone decided to participate in
the study. Of those only 41% were randomized. Partici-
pants enrolled in our study may represent individuals who
are more motivated or compliant compared to individuals
with T2DM in the general population.
Aside from these limitations, some strengths of this
study deserve mention. To our knowledge, it is first study
to evaluate and compare the multilevel outcomes of be-
havioral and technological self-management techniques in
a multi-setting population. It is also one of the first studies
to evaluate and compare these interventions in a racially/
ethnically diverse population in a practice setting outside
of testing done by the original program developers. It
therefore provides important exploratory data, shaping
our knowledge and understanding of factors which may
be important to minority and ethnic populations in adopt-
ing diabetes self-management techniques.
Conclusions
In conclusion, we found that although behavioral and
technological interventions can result in some modest im-
provements in glycemic control, these interventions did
not fare significantly better than usual care in achieving
glycemic control. More research is needed to understand
how these interventions can be most effective in clinical
practice. The reduction in HbA1c levels found in our con-
trol group that received usual care also suggests that good
routine care in an integrated healthcare system can also
lead to better glycemic control. We also recommend fur-
ther studies that will be powered enough to examine ra-
cial/ethnic differences in glycemic control.
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